OpGen Data Predicting Antibiotic Resistance Published in Antimicrobial Agents and Chemotherapy Journal
March 28 2019 - 6:30AM
OpGen, Inc. (Nasdaq: OPGN) announced today that data supporting
prediction of antibiotic resistance using the company’s Acuitas®
AMR Gene Panel and Acuitas Lighthouse Software was published in the
April issue of Antimicrobial Agents and Chemotherapy, a
peer-reviewed scientific journal from the American Society for
Microbiology. The manuscript titled ”Predicting Antibiotic
Resistance in Gram-Negative Bacilli from Resistance Genes” was
authored by a team of OpGen researchers, led by Dr. Terry Walker,
Sr. VP, Research & Development.
The manuscript highlights results from a rapid,
high-throughput PCR test that evaluated more than 7,500 highly
antibiotic-resistant clinical isolates of Escherichia coli,
Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas
aeruginosa selected from Merck’s Study for Monitoring Antimicrobial
Resistance Trends (SMART) surveillance network to predict
phenotypic resistance to several antibiotic classes.
The study developed statistical methods to
predict phenotypic resistance from resistance genes for various
combinations of the four bacterial species and the antibiotics
gentamicin, tobramycin, ciprofloxacin, levofloxacin,
trimethoprim-sulfamethoxazole, ertapenem, imipenem, cefazolin,
cefepime, cefotaxime, ceftazidime, ceftriaxone, ampicillin,
piperacillin and aztreonam. Average positive predictive values
for predicting phenotypic resistance were 91% for E. coli, 93% for
K. pneumoniae, 87% for P. mirabilis, and 92% for P. aeruginosa.
Dr. Walker noted, “We believe this study is the
most comprehensive of its kind completed to date. The results
support the use of rapid DNA testing to help guide antibiotic
decision making. The study evaluated approximately two million data
points from patients globally and in the United States. Forty-one
proprietary prediction algorithms based on the study results have
been coded into the Acuitas Lighthouse Software for use in OpGen’s
planned diagnostic product offerings.” Dr. Walker continued, “We
are close to making our first FDA submission for the Acuitas AMR
Gene Panel (Isolates) test and we are working to successfully
complete FDA submissions for use of the AMR Gene Panel and the
Acuitas Lighthouse Software for detection and management of urinary
tract infections in under three hours. These products are currently
available for Research Use Only.”
Representatives of Intermountain Medical Center,
University of Utah, Merck, and IHMA, Inc. were also part of the
research team. For more information on Antimicrobial Agents and
Chemotherapy, or to access the latest issue, please click here.
About OpGen
OpGen, Inc. is a precision medicine company
harnessing the power of molecular diagnostics and informatics to
help combat infectious disease. We are developing molecular
information products and services for global healthcare settings,
helping to guide clinicians with more rapid and actionable
information about life threatening infections, improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs.
Our molecular diagnostics and informatics
products, product candidates and services combine our Acuitas®
molecular diagnostics and Acuitas Lighthouse® informatics platform
for use with our proprietary, curated MDRO knowledgebase. We are
working to deliver our products and services, some in development,
to a global network of customers and partners. The Acuitas AMR Gene
Panel (RUO) is intended for Research Use Only and is not for
use in diagnostic procedures. The Acuitas Lighthouse Software is
not distributed commercially for antibiotic resistance prediction
and is not for use in diagnostic procedures. For more information,
please visit www.opgen.com.
OpGen, Acuitas, and Acuitas
Lighthouse are registered trademarks of OpGen, Inc.
OpGen Contact: Michael Farmer Vice President,
Marketing (240)
813-1284mfarmer@opgen.comInvestorRelations@opgen.com
Press Contact:Matthew BretziusFischTank
Marketing and PRmatt@fischtankpr.com
Investor Contacts: Joe GreenEdison
Groupjgreen@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2023 to Sep 2024